Carla V. Rothlin is an Argentinian immunologist.She is professor of immunobiology at Dorys McConnell Duberg and professor of pharmacology at Yale University. Rothlin is also the co-leader of the Cancer Immunology Program at Yale Cancer Center as well as an Howard Hughes Medical Investigator faculty scholar.
Carla V. Rothlin | |
|---|---|
 Rothlin speaks at the National Institutes of Health in 2018 | |
| Born | Buenos Aires, Argentina |
| Alma mater | University of Buenos Aires Salk Institute for Biological Studies |
| Known for | Role of TAM receptor tyrosine kinases in immune homeostasis |
| Awards | Howard Hughes Medical Institute Faculty Scholar, Early Excellence Award – American Asthma Foundation, Pew Foundation Fellow |
| Scientific career | |
| Fields | Immunology |
| Institutions | Yale University Yale Cancer Center |
Rothlin studies the mechanisms that regulate immune homeostasis and wound repair, with specific interests in cell death recognition, immune checkpoints, and cellular crosstalk in the context of injury and cell turnover. She has made fundamental discoveries about the roles of TAM receptors tyrosine kinase and their ligands in the regulation of inflammation. Rothlin is also a co-founder of the Global Immunotalks, a weekly series of virtual lectures on recent immunological research. The series began in 2020.[1]
Early life and education
Rothlin grew up in Buenos Aires, Argentina.[2] She was one of four girls, raised by her mother, a physician, and her father, a pharmacology researcher.[2] Rothlin was surrounded by laboratory science and clinical cases from a young age.[2]
After high school, Rothlin earned both undergraduate and graduate degrees in biochemistry from the University of Buenos Aires,[3] where was mentored by Ana Belén Elgoyhen and studied the biochemical properties of the nicotinic acetylcholine receptors in the inner ear.[4] Her work helped further scientific understanding of how efferent cholinergic fibers and inner ear hair cells communicate information from the brain back to the ear to mediate sensory tuning.[5][3]
Rothlin completed her graduate studies in 2002 and moved to San Diego, California for her postdoctoral work,[2] where she studied under Greg Lemke at the Salk Institute for Biological Studies. There, she became fascinated by TAM receptors, which Lemke had discovered in the 1990s, and their roles in immune homeostasis.[2] She then decided to study immunology in her postdoctoral research.[6]
During her postdoctoral studies, Rothlin was part of a team that discovered the role of TAM receptor tyrosine kinases, Tyro3, Axl, and MerTk, in the regulation of inflammation.[7] They found that Tyro3, Axl, and MerTk inhibit Toll-like receptor (TLR) and TLR-induced cytokine cascades in the innate immune response.[8] Specifically, cytokine-dependent TAM signalling is upregulated by type I interferon-STAT1 signalling leading to expression of cytokine and TLR suppressors, acting in an inflammatory negative feedback loops.[8]
Career and research
In 2009, Rothlin was recruited to Yale University, where she started a lab with her partner from Salk, Sourav Ghosh.[2] Rothlin became Assistant Professor of Immunobiology at Yale, and in 2016 joined the faculty of the Howard Hughes Medical Institute.[9] In 2018, Rothlin became director of Graduate Studies in Immunobiology at Yale.[10] In 2019, Rothlin was appointed Dorys McConnell Duberg Professor of Immunobiology.[10] She is also a Professor of Pharmacology as well as a member of the Yale Cancer Center and Co-Leader of the Cancer Immunology Program at Yale.[11]
Rothlin is a co-director of the Rothlin Ghosh Lab which focuses on exploring the mechanisms of immune regulation and homeostasis.[12] The Rothlin Gosh lab has made critical discoveries regarding TAM receptor tyrosine kinases, their ligands and the role their interactions serve as innate immune checkpoints in the regulation of the immune response.[7] They have specifically found that TAMs help to inhibit the innate immune response, that TAM ligand, protein S, can mediate the ability of T cells to limit dendritic cell activation, and their roles in control of type 2 immunity and phagocytosis of apoptotic cells.[13]
TAM receptors and immune homeostasis
Rothlin and her team discovered a mechanism by which the adaptive immune system helps to regulate chronic inflammation through controlling dendritic cells (DCs).[14] They found that T cells produce the TAM ligand, protein S, that acts on TAMs on DCs to limit the extent of their activation.[14] When they knocked out the Pros1 gene, encoding protein S, in T cells, they found an enhanced immune response and increased colitis.[14] They further proved that this mechanism of immune regulation in conserved in humans as well.[14] They further showed a mechanism by which viruses can take advantage of the TAM mediated immune regulation to avoid destruction.[15] They found that viruses coated with TAM ligands activate TAMs on dendritic cells which limits interferon signalling to help evade immune responses and enable replication.[15] Since they also showed that inhibiting TAM receptors can promote resistance to infection, this could be used as a therapeutic target for viral diseases.[15] In 2015, Rothlin's group characterized MERTK as a potent inhibitor of T cell activation through its interactions with Pros1 ligand in humans.[16]
Innate immune checkpoints in cancer
Rothlin's lab also explores the role TAMs play in cellular immunology and innate immune checkpoints in cancer.[6] Immune checkpoint blockade therapy has historically focused on the adaptive immune system, blocking the cellular breaking system on T cells (such as CTLA-4 and PD-1 inhibitors) to enhance immunogenicity of the tumor microenvironment and cytotoxicity tumor infiltrating cells.[17] Rothlin and her team are working upstream of T cell exhaustion markers, at the level of the innate immune system checkpoints which involve TAMs.[17] Since Rothlin found that TAMs help to mediate the repair and regrowth aspect of the innate immune response, blocking these molecules holds promise to keep the immune system in an inflammatory or defensive state to promote anti-tumor immunity.[17]
In collaboration with Miriam Merad’s group, Rothlin and her team found that Axl signalling induces the expression of PD-L1 on dendritic cells in the tumor environment, supporting the TAM receptor pathway as an upstream target for immunotherapy.[18] In 2017, Rothlin and her team showed further roles of Axl in tumor growth.[19] They found that Axl expression is upregulated in colorectal cancer and that limiting Axl expression prevented tumor cell migration and invasion.[19] They also found that Axl plays a role in B cell migration to tertiary lymphoid structures in cancer, and blocking Axl signalling limits B cell migration.[20]
Scientific outreach
Rothlin aims to improve the scientific community through her leadership roles and outreach projects.[1] Rothlin is a committee member for the Minority Affairs Committee for the American Association of Immunologists.[21] She is also a senior editor for Immunology and Inflammation at eLife.[22]
Rothlin is also the co-founder of the Global Immunotalks Lectures, which she started in 2020 along with her colleague, friend, and fellow immunologist Elina Zúñiga in an effort to make cutting-edge immunology accessible to a global audience without the need for travel.[6][23] Rothlin and Zúñiga invite a renowned immunologist to share their newest findings with a global audience over Zoom every Wednesday. The talks are recorded and posted to YouTube.[6] Rothlin and Zúñiga were also motivated to implement these talks as a way to increase the opportunities for access to the latest discoveries in an egalitarian manner.[1] They know from firsthand experience in Argentina that not everyone has access to the seminars and conferences that some laboratories do.[23] Global Immunotalks proved to be very successful at bringing people together virtually during the COVID-19 pandemic.[6] The event was so successful, the series is being continued into 2021.[1]
Awards and honors
- 2020 Career Enhancement Program and Developmental Research Program Awards[24]
- 2016 Howard Hughes Medical Institute Faculty Scholar[9]
- 2011 Early Excellence Award – American Asthma Foundation[25]
- 2011 Novel Research Grant – Lupus Research Institute[6]
- 2010 Senior Research Award – Crohn's and Colitis Foundation of America[3]
- 2008 Special Fellow – Leukemia and Lymphoma Society[3]
- 2008 Scientist Development Award – American Heart Association[3]
- 2002 Pew Foundation Fellow[3]
- 2002 Bernardo Houssay Award – Sociedad Argentina de Biologia[3]
Select publications
- Bosurgi L, Cao YG, Cabeza-Cabrerizo M, Tucci A, Hughes LD, Kong Y, Weinstein JS, Licona-Limon P, Schmid ET, Pelorosso F, Gagliani N, Craft JE, Flavell RA, Ghosh S, Rothlin CV. Macrophage function in tissue repair and remodeling requires IL-4 or IL-13 with apoptotic cells. Science. 2017 Jun 9;356(6342):1072–1076. doi: 10.1126/science.aai8132. Epub 2017 May 11. PMID 28495875; PMCID: PMC5556699.[26]
- Schmid ET, Pang IK, Carrera Silva EA, Bosurgi L, Miner JJ, Diamond MS, Iwasaki A, Rothlin CV. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. Elife. 2016 Jun 28;5:e12414. doi: 10.7554/eLife.12414. PMID 27350258; PMCID: PMC4924996.[27]
- Chan PY, Carrera Silva EA, De Kouchkovsky D, Joannas LD, Hao L, Hu D, Huntsman S, Eng C, Licona-Limón P, Weinstein JS, Herbert DR, Craft JE, Flavell RA, Repetto S, Correale J, Burchard EG, Torgerson DG, Ghosh S, Rothlin CV. The TAM family receptor tyrosine kinase TYRO3 is a negative regulator of type 2 immunity. Science. 2016 Apr 1;352(6281):99–103. doi: 10.1126/science.aaf1358. PMID 27034374; PMCID: PMC4935984.[28]
- Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, Aldape K, Sanai N, Rothlin CV, Ghosh S. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNFα in glioblastoma. Sci Signal. 2014 Aug 12;7(338):ra75. doi: 10.1126/scisignal.2005196. PMID 25118327; PMCID: PMC4486020.[29]
- Rothlin CV, Leighton JA, Ghosh S. Tyro3, Axl, and Mertk receptor signaling in inflammatory bowel disease and colitis-associated cancer. Inflamm Bowel Dis. 2014 Aug;20(8):1472-80. doi: 10.1097/MIB.0000000000000050. PMID 24846720; PMCID: PMC4343000.[30]
- Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, Lemke G. TAM receptors are pleiotropic inhibitors of the innate immune response. Cell. 2007 Dec 14;131(6):1124-36. doi: 10.1016/j.cell.2007.10.034. PMID 18083102.[8]
- Rothlin CV, Lioudyno MI, Silbering AF, Plazas PV, Casati ME, Katz E, Guth PS, Elgoyhen AB. Direct interaction of serotonin type 3 receptor ligands with recombinant and native alpha 9 alpha 10-containing nicotinic cholinergic receptors. Mol Pharmacol. 2003 May;63(5):1067–74. doi: 10.1124/mol.63.5.1067. PMID 12695535.[4]